← AI Companies
Consumer telehealth company offering personalized health, wellness and prescription products via an online platform.
Snapshot
| Country |
USA
|
| Exchange | NYSE |
| AI Layer |
app
|
| Sentiment |
62.0% |
| USD Mkt Cap | 6.42B |
| USD Revenue | 2.58B |
| USD Net Income | -142.03M |
| fwd P/E | 33.67 |
| PEG | 2.53 |
| Price 3M | +0.3% |
| Price 6M | +10.3% |
| Price 1Y | -50.8% |
| Price 2Y | +64.8% |
| USD Share Price | 27.31 |
Price & Size
| Price |
27.51 USD |
| Market Cap |
6.42B USD |
| Shares Outstanding |
224.94M |
| Shares Float |
213.69M |
| 52w Low |
13.74 USD |
| 52w High |
65.30 USD |
| Avg Volume |
14.29M |
Valuation
| P/E (forward) |
33.7x |
| P/B |
19.81x |
| Enterprise Value |
7.12B USD |
| Book Value / Share |
1.39 USD |
| PEG Ratio |
2.53x |
| P/S |
2.49x |
| EV / Revenue |
2.76x |
| EV / EBITDA |
-699.98x |
Income
| Revenue |
2.58B USD |
| Revenue / Share |
11.29 USD |
| EBITDA |
-10.18M USD |
| Net Income |
-142.03M USD |
| EPS (trailing) |
-0.64 USD |
| EPS (forward) |
0.82 USD |
Margins & Profitability
| Gross Margin |
69.5% |
| Operating Margin |
-12.8% |
| Profit Margin |
-5.5% |
| EBITDA Margin |
-0.4% |
| Return on Equity |
-32.0% |
| Return on Assets |
-2.2% |
Cash & Debt
| Total Cash |
841.05M USD |
| Total Debt |
1.55B USD |
| Free Cash Flow |
849.44M USD |
| Operating Cash Flow |
263.45M USD |
| Debt / Equity |
4.77x |
| Current Ratio |
0.93x |
| Quick Ratio |
0.82x |
Analyst Consensus
| Target (Mean) |
31.23 USD |
| Target (Median) |
31.00 USD |
| Target (High) |
42.00 USD |
| Target (Low) |
23.00 USD |
| Recommendation |
hold |
| # Analysts |
13 |
Identifiers
| ISIN | US4330001060 |
| CUSIP | 433000106 |
| FIGI | BBG00Q53VZ35 |
| SEDOL | BJRD2V9 |
Sentiment 62.0%
as of Sep 11, 2026
Positive drivers
Strong subscriber growth in telehealth services and expansion into AI-driven personalized wellness plans boosted investor optimism. Positive earnings surprises and partnerships with major insurers highlighted operational efficiency gains. Rising demand for men's and women's health products aligned with broader digital health trends.
Neutral / mixed
Market volatility in the broader healthcare sector created mixed signals, with some analysts noting dependency on regulatory approvals for new offerings. Seasonal fluctuations in user engagement were observed without clear directional impact. Ongoing competition from established pharma players balanced out growth narratives.
Negative drivers
Concerns over potential FDA scrutiny on compounded medications weighed on sentiment during the period. Rising marketing costs and customer acquisition expenses pressured margins in quarterly reports. Macroeconomic uncertainty around interest rates affected high-growth tech-health stocks like HIMS.
Bottom line
Overall sentiment remains moderately positive driven by growth metrics, tempered by regulatory and cost-related risks in a competitive landscape.